[{"Assets_0_Q3_USD":166613000.0,"CommonStockSharesOutstanding_0_Q3_shares":270877229.0,"EarningsPerShareBasic_1_Q3_USD":-0.04,"EarningsPerShareBasic_3_Q3_USD":-0.17,"EarningsPerShareDiluted_1_Q3_USD":-0.04,"EarningsPerShareDiluted_3_Q3_USD":-0.17,"NetIncomeLoss_1_Q3_USD":-10825000.0,"NetIncomeLoss_3_Q3_USD":-45400000.0,"StockholdersEquity_0_Q3_USD":-46109000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":270803000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":270566000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":270803000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":270566000.0,"Ticker":"AMRN","CIK":"897448","name":"AMARIN CORP PLCUK","OfficialName":"Amarin Corporation plc","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1265593617.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171101"}]